CARsgen Therapeutics Holdings Ltd. (HK:2171) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
CARsgen Therapeutics Holdings Ltd. announced promising results from a pivotal Phase II clinical trial for their CAR T-cell therapy, satricabtagene autoleucel, in treating advanced gastric and gastroesophageal junction cancers. The study demonstrated a statistically significant improvement in progression-free survival, positioning satri-cel as a potential first-in-class treatment. With this advancement, CARsgen continues to enhance its reputation in innovative cancer therapies, focusing on solid tumors.
For further insights into HK:2171 stock, check out TipRanks’ Stock Analysis page.